ObjectiveTo assess the significance of peritumoral features based on deep learning in classifying non-spiculated and noncalcified masses (NSNCM) on mammography.MethodsWe retrospectively screened the digital mammography data of 2254 patients who underwent surgery for breast lesions in Harbin Medical University Cancer Hospital from January to December 2018. Deep learning and radiomics models were constructed. The classification efficacy in ROI and patient levels of AUC, accuracy, sensitivity, and specificity were compared. Stratified analysis was conducted to analyze the influence of primary factors on the AUC of the deep learning model. The image filter and CAM were used to visualize the radiomics and depth features.ResultsFor 1298 included patients, 771 (59.4%) were benign, and 527 (40.6%) were malignant. The best model was the deep learning combined model (2 mm), in which the AUC was 0.884 (P < 0.05); especially the AUC of breast composition B reached 0.941. All the deep learning models were superior to the radiomics models (P < 0.05), and the class activation map (CAM) showed a high expression of signals around the tumor of the deep learning model. The deep learning model achieved higher AUC for large size, age >60 years, and breast composition type B (P < 0.05).ConclusionCombining the tumoral and peritumoral features resulted in better identification of malignant NSNCM on mammography, and the performance of the deep learning model exceeded the radiomics model. Age, tumor size, and the breast composition type are essential for diagnosis.
Background: Isocitrate dehydrogenase (IDH) mutation status is an important biomarker for the treatment strategy selection and prognosis evaluation of glioma. The purpose of this study is to predict the IDH mutation status of gliomas based on multicenter magnetic resonance (MR) images using radiomic models, which were composed from the selected radiomics features and logistic regression (LR), support vector machine (SVM), and LR least absolute shrinkage and selection operator (LASSO) classifiers. Methods:We retrospectively reviewed the medical records of 205 patients with gliomas. We enrolled 78 patients from Shandong Provincial Hospital from January 2018 to December 2019 as testing sets and 127 patients from The Cancer Genome Atlas (TCGA) as training sets. Preoperative MR images were stratified according to their IDH status, and the participants formed a consecutive and random series. Four MR modalities, including T1C, T2, T1 fluid-attenuated inversion recovery (FLAIR), and T2 FLAIR, were used for analysis. Five-fold cross-validation was adopted to train the models, and the models' performances were verified through the testing set. Tumor volumes of interest (VOI) were delineated on the 4 MR modalities. A total of 428 radiomics features were extracted. Two feature selection algorithms, Pearson correlation coefficient (PCC) and recursive feature elimination (RFE), were used to select radiomics features.These features were fed into 3 machine learning classifiers, which were LR, SVM, and LR LASSO, to construct prediction models. The accuracy (ACC), sensitivity (SEN), specificity (SPEC), and area under the curve (AUC) were applied to measure the predictive performance of the radiomics models. Results:The LR (SVM and LR LASSO) classifier predicted IDH mutation status with an average testing set ACC of 80.77% (80.64% and 80.41%), a SEN of 73.68% (84.21% and 89.47%), a SPEC of 87.50% (67.50% and 62.50%), and an AUC of 0.8572 (0.8217 and 0.8164). Conclusions:The radiomics models based on MR modalities demonstrated the potential to be used as tools across different data sets for the noninvasive prediction of the IDH mutation status in glioma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.